Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells:: A possible role for PPARγ in endothelial function

被引:123
作者
Kato, K [1 ]
Satoh, H
Endo, Y
Yamada, D
Midorikawa, S
Sato, W
Mizuno, K
Fujita, T
Tsukamoto, K
Watanabe, T
机构
[1] Fukushima Med Univ, Sch Med, Dept Internal Med 3, Fukushima 9601295, Japan
[2] Fukushima Med Univ, Sch Med, Dept Biochem, Fukushima 9601295, Japan
[3] Fukushima Med Univ, Sch Med, Dept Ecol & Clin Therapeut, Fukushima 9601295, Japan
[4] Univ Tokyo, Sch Med, Dept Internal Med 1, Tokyo 1138655, Japan
关键词
thiazolidinediones; plasminogen activator inhibitor type 1; human umbilical vein endothelial cell; peroxisome proliferator-activated receptor gamma;
D O I
10.1006/bbrc.1999.0648
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effect of peroxisome proliferator-activated receptor (PPAR) gamma activators, thiazolidinediones, on plasminogen activator type 1 (PAI-1) was examined in cultured human umbilical vein endothelial cells (HUVEC), Tumor necrosis factor alpha (TNF-alpha) enhanced PAI-1 secretion and mRNA expression by approximately 2-fold. The thiazolidinediones, troglitazone and pioglitazone, decreased basal and TNF-alpha-stimulated PAI-1 secretion and mRNA expression in HUVEC in a dose-dependent fashion. PPAR gamma mRNA in HUVEC could be detected by reverse transcriptase-polymerase chain reaction using specific primers. These results suggest that PPAR gamma may regulate PAI-1 expression in HUVEC and that thiazolidinediones have a therapeutic potential for improving endothelial dysfunction observed in insulin resistance. (C) 1999 Academic Press.
引用
收藏
页码:431 / 435
页数:5
相关论文
共 25 条
  • [1] ANWERX J, 1988, ARTERIOSCLEROSIS, V8, P68
  • [2] BOSMA PJ, 1988, J BIOL CHEM, V263, P9129
  • [3] SUPPRESSION OF HEPATIC GLUCONEOGENESIS IN LONG-TERM TROGLITAZONE TREATED DIABETIC KK AND C57BL/KSJ-DB/DB MICE
    FUJIWARA, T
    OKUNO, A
    YOSHIOKA, S
    HORIKOSHI, H
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (04): : 486 - 490
  • [4] Greene M. E., 1995, Gene Expression, V4, P281
  • [5] Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats
    Hayakawa, T
    Shiraki, T
    Morimoto, T
    Shii, K
    Ikeda, H
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 223 (02) : 439 - 444
  • [6] ADIPOSE EXPRESSION OF TUMOR-NECROSIS-FACTOR-ALPHA - DIRECT ROLE IN OBESITY-LINKED INSULIN RESISTANCE
    HOTAMISLIGIL, GS
    SHARGILL, NS
    SPIEGELMAN, BM
    [J]. SCIENCE, 1993, 259 (5091) : 87 - 91
  • [7] PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
    Jiang, CY
    Ting, AT
    Seed, B
    [J]. NATURE, 1998, 391 (6662) : 82 - 86
  • [8] JUHANVAGUE I, 1992, FIBRINOLYSIS, V6, P100
  • [9] TUMOR-NECROSIS-FACTOR-ALPHA INDUCED PHOSPHORYLATION OF INSULIN-RECEPTOR SUBSTRATE-1 (IRS-1) - POSSIBLE MECHANISM FOR SUPPRESSION OF INSULIN-STIMULATED TYROSINE PHOSPHORYLATION OF IRS-1
    KANETY, H
    FEINSTEIN, R
    PAPA, MZ
    HEMI, R
    KARASIK, A
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (40) : 23780 - 23784
  • [10] KATO K, 1998, J JAPAN DIAB SOC, V41, pS215